Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Equities research analysts at Leede Financial boosted their FY2025 earnings per share (EPS) estimates for shares of ...

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

Oncolytics Biotech (ONCY) has disclosed a new risk, in the Corporate Activity and Growth category. Oncolytics Biotech faces significant business ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year ...

Oncolytics Biotech ( ($ONCY) ) has released its Q4 earnings. Here is a breakdown of the information Oncolytics Biotech presented to its investors.

Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model ...

RBC Capital lowered the firm’s price target on Oncolytics (ONCY) to C$5 from C$6 and keeps an Outperform rating on the shares.Optimize Your ...

CNW/ -- (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today ...

Of 12 evaluable patients, four experienced a partial response, translating to a 33% response rate, while one patient achieved a complete response with no detectable cancer for over 15 months. By ...

USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never ...